In renal cell carcinoma, gastric cancer, and other cancer patients, PD-L1 expression is known to be associated with poor prognosis [10–12], indicating that PD-L1 could be an important regulator of the immune system when it fights against cancer. This evidence concerns the gene CD274 and cancer.